{
  "metadata": {
    "case_id": 19,
    "model": "GPT-5.1",
    "timestamp": "2025-11-29T15:07:41.959044",
    "total_alignments": 3,
    "target_section": "protocolSection",
    "ground_truth_path": "/{YOURPATH}/samples/CTG/protocolSection/1_100/19_NCT02679807.json",
    "prediction_path": "/{YOURPATH}/restructured_outputs_protocol/GPT-5.1/19_GPT-5.1.json",
    "shard_range": "1_100"
  },
  "alignments": [
    {
      "field_path": "protocolSection.armsInterventionsModule.armGroups",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 2,
      "similarity_matrix": [
        [
          0.95,
          0.3
        ],
        [
          0.35,
          0.9
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.95,
          "status": "matched",
          "ref_item": {
            "label": "Bifidobacterium lactis Bl-04",
            "type": "ACTIVE_COMPARATOR",
            "description": "2\\*109 cfus of probiotic Bifidobacterium lactis Bl-04 (DuPont Nutrition and Health) mixed with 1g of sucrose as a carrier",
            "interventionNames": [
              "Biological: Bifidobacterium animalis subsp. lactis Bl-04"
            ]
          },
          "pred_item": {
            "label": "Bl-04 Probiotic",
            "type": "EXPERIMENTAL",
            "description": "Participants received oral Bifidobacterium animalis subsp. lactis Bl-04 daily for 28 days prior to and through 14 days after experimental rhinovirus A39 challenge. The probiotic was provided in single-use sachets containing at least 2 × 10^9 CFU of Bl-04 mixed with 1 g sucrose as a carrier.",
            "interventionNames": [
              "Bifidobacterium animalis subsp. lactis Bl-04",
              "Rhinovirus A39 challenge"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "sucrose",
            "interventionNames": [
              "Other: sucrose"
            ]
          },
          "pred_item": {
            "label": "Placebo",
            "type": "PLACEBO_COMPARATOR",
            "description": "Participants received an oral placebo daily for 28 days prior to and through 14 days after experimental rhinovirus A39 challenge. The placebo was provided in single-use sachets containing 1 g sucrose, identical in appearance, smell, and taste to the probiotic sachets but without Bl-04.",
            "interventionNames": [
              "Placebo sachet (sucrose)",
              "Rhinovirus A39 challenge"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.armsInterventionsModule.interventions",
      "algorithm": "hungarian",
      "ref_count": 2,
      "pred_count": 3,
      "similarity_matrix": [
        [
          0.96,
          0.2,
          0.18
        ],
        [
          0.2,
          0.9,
          0.05
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.96,
          "status": "matched",
          "ref_item": {
            "type": "BIOLOGICAL",
            "name": "Bifidobacterium animalis subsp. lactis Bl-04",
            "armGroupLabels": [
              "Bifidobacterium lactis Bl-04"
            ]
          },
          "pred_item": {
            "type": "DIETARY_SUPPLEMENT",
            "name": "Bifidobacterium animalis subsp. lactis Bl-04",
            "description": "Oral probiotic supplement containing a minimum of 2 × 10^9 colony forming units of Bifidobacterium animalis subsp. lactis Bl-04 mixed with 1 g sucrose as a carrier, administered once daily in sachet form from day -28 to day 14 relative to viral challenge.",
            "armGroupLabels": [
              "Bl-04 Probiotic"
            ]
          }
        },
        {
          "ref_idx": 1,
          "pred_idx": 1,
          "score": 0.9,
          "status": "matched",
          "ref_item": {
            "type": "OTHER",
            "name": "sucrose",
            "armGroupLabels": [
              "Placebo"
            ]
          },
          "pred_item": {
            "type": "DIETARY_SUPPLEMENT",
            "name": "Placebo sachet (sucrose)",
            "description": "Oral placebo supplement consisting of a sachet containing 1 g sucrose, identical in appearance, smell, and taste to the active Bl-04 product but without probiotic bacteria, administered once daily from day -28 to day 14 relative to viral challenge.",
            "armGroupLabels": [
              "Placebo"
            ]
          }
        }
      ]
    },
    {
      "field_path": "protocolSection.outcomesModule.primaryOutcomes",
      "algorithm": "hungarian",
      "ref_count": 1,
      "pred_count": 1,
      "similarity_matrix": [
        [
          0.86
        ]
      ],
      "matched_pairs": [
        {
          "ref_idx": 0,
          "pred_idx": 0,
          "score": 0.86,
          "status": "matched",
          "ref_item": {
            "measure": "Number of Participants With Rhinovirus-associated Illness Episodes",
            "description": "Rhinovirus-associated illness episodes: Volunteers who have both a rhinovirus infection and a symptomatic illness will be defined as having a rhinovirus-associated common cold illness.",
            "timeFrame": "5 days"
          },
          "pred_item": {
            "measure": "Incidence of rhinovirus-associated illness",
            "description": "Proportion of participants who develop a protocol-defined rhinovirus-associated illness, defined as meeting the study criteria for symptomatic illness (total modified Jackson symptom score ≥6 plus either three days of rhinorrhea or the subjective impression of having had a common cold) in volunteers who are infected with RV-A39 (virus isolated from at least one post-challenge specimen or ≥4-fold rise in serum neutralizing antibody titer).",
            "timeFrame": "From rhinovirus challenge (day 0) through 14 days post-challenge"
          }
        }
      ]
    }
  ]
}